Dapsone for chronic autoimmune thrombocytopenic purpura: a report of 66 cases

doi:10.1046/j.1365-2141.1997.412687.x

If you are seeing this message, you may be experiencing temporary network problems. Please wait a few minutes and refresh the page. If the problem persists, you may wish to report it to your local Network Manager.

It is also possible that your web browser is not configured or not able to display style sheets. In this case, although the visual presentation will be degraded, the site should continue to be functional. We recommend using the latest version of Microsoft or Mozilla web browser to help minimise these problems.

Wiley InterScience

British Journal of Haematology

Volume 97 Issue 2, Pages 336 - 339

Published Online: 29 Oct 2003

The Official Journal of the British Society for Haematology

Go to Society Site

< Previous Abstract | Next Abstract >

Save Article to My Profile Download Citation Request Permissions

Abstract | Full Text: PDF (Size: 380K) | Related Articles | Citation Tracking

Dapsone for chronic autoimmune thrombocytopenic purpura: a report of 66 cases

Bertrand Godeau , Jean-Marc Durand , Françoise Roudot-Thoraval , Anne Tennezé , Eric Oksenhendler , Gilles Kaplanski , Annette Schaeffer & Philippe Bierling

¹ Service de Médecine Interne ² Laboratoire d'Immunologie Leuco-plaquettaire ³ Département de Santé Publique et de Biostatistique, Hôpital Henri Mondor, Créteil ⁴ Service de Médecine Interne, Hôpital Sainte Marguerite, Marseille ⁵ Service d'Immunopathologie, Hôpital Saint Louis, Paris, France

Correspondence to: Dr Philippe Bierling

KEYWORDS

autoimmune thrombocytopenic purpura • dapsone • thrombocytopenia

ABSTRACT

Sixty-six adults with chronic autoimmune thrombocytopenic purpura AITP and platelet count <50 ×10⁹ l were treated with dapsone (75–100 mg orally). A response was observed in 33 patients. The median duration of treatment required to obtain a response was 21 d (range 8–90). The median maximal platelet count on treatment was 130 × 10⁹ l (range 71–355). Dapsone was continued in 20/33 responders for a median of 12.5 months (range 1–48) and the response persisted in 19. Treatment was intentionally withdrawn in the other 13 responders and thrombocytopenia immediately recurred in 12. Reversible side-effects required cessation of treatment in seven patients. These results demonstrate that dapsone is an effective, inexpensive, and well-tolerated treatment for chronic AITP.

DIGITAL OBJECT IDENTIFIER (DOI)

10.1046/j.1365-2141.1997.412687.x About DOI